Development of a prognostic nomogram for esophageal squamous cell carcinoma patients received radiotherapy based on clinical risk factors

TL;DR

This study developed a reliable tool to predict survival outcomes for esophageal cancer patients undergoing radiotherapy using clinical risk factors.

Contribution

A novel nomogram was developed to predict locoregional recurrence-free survival in ESCC patients after radiotherapy.

Findings

The nomogram outperformed the TNM staging system in predicting locoregional recurrence-free survival.

The nomogram accurately categorized patients into low, medium, and high-risk groups with significant survival differences.

Clinical risk factors like T stage, N stage, and tumor volume were identified as key predictors.

Abstract

The goal of the study was to create a nomogram based on clinical risk factors to forecast the rate of locoregional recurrence-free survival (LRFS) in patients with esophageal squamous cell carcinoma (ESCC) who underwent radiotherapy (RT).

In this study, 574 ESCC patients were selected as participants. Following radiotherapy, subjects were divided into training and validation groups at a 7:3 ratio. The nomogram was established in the training group using Cox regression. Performance validation was conducted in the validation group, assessing predictability through the C-index and AUC curve, calibration via the Hosmer-Lemeshow (H-L) test, and evaluating clinical applicability using decision curve analysis (DCA).

T stage, N stage, gross tumor volume (GTV) dose, location, maximal wall thickness (MWT) after RT, node size (NS) after RT, Δ computer tomography (CT) value, and chemotherapy were found to be independent risk factors that impacted LRFS by multivariate cox analysis, and the findings could be utilized to create a nomogram and forecast LRFS. the area under the receiver operating characteristic (AUC) curve and C-index show that for training and validation groups, the prediction result of LRFS using nomogram was more accurate than that of TNM. The LRFS in both groups was consistent with the nomogram according to the H-L test. The DCA curve demonstrated that the nomogram had a good prediction effect both in the groups for training and validation. The nomogram was used to assign ESCC patients to three risk levels: low, medium, or high. There were substantial variations in LRFS between risk categories in both the training and validation groups (p<0.001, p=0.003).

For ESCC patients who received radiotherapy, the nomogram based on clinical risk factors could reliably predict the LRFS.

Figures